Who Says FDA Can't Have Your Marketing Plan?
This article was originally published in RPM Report
Executive Summary
Industry fought hard to prohibit FDA from having the authority to review marketing plans as part of FDAAA. The REMS for Xenazine suggests that the legislative success may have been a Pyrrhic victory; FDA is going ahead and grabbing authority over the marketing plans and procedures for some drugs.